Alterity Launches SPP, Institutional Backing Guarantees Capital Raise
Ticker: PRNAF · Form: 6-K · Filed: Jan 11, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: capital-raise, equity-offering, institutional-support, biotechnology
TL;DR
**Alterity's capital raise is a go, institutional investors are covering any SPP shortfall.**
AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) launched a Security Purchase Plan (SPP) on January 11, 2024, to raise capital. Crucially, the company has secured written commitments from institutional shareholders to buy any shares not purchased by existing retail shareholders through the SPP. This commitment ensures the company will successfully raise the intended capital, which is important for investors as it provides financial stability for their ongoing neurodegenerative disease treatment development.
Why It Matters
This filing matters because it signals Alterity Therapeutics' ability to secure funding for its operations, reducing financial uncertainty and supporting its drug development efforts for neurodegenerative diseases.
Risk Assessment
Risk Level: low — The commitment from institutional shareholders significantly de-risks the capital raise, ensuring the company will receive the necessary funds.
Analyst Insight
A smart investor would view this as a positive development, as it removes a significant funding risk for Alterity Therapeutics, potentially stabilizing the stock and supporting future growth initiatives.
Key Players & Entities
- Alterity Therapeutics Limited (company) — the registrant launching the SPP
- Geoffrey P. Kempler (person) — Chairman who signed the 6-K report
- January 11, 2024 (date) — date of the 6-K filing and SPP launch
- institutional shareholders (company) — investors committed to purchasing remaining SPP shares
Forward-Looking Statements
- Alterity Therapeutics will successfully complete its Security Purchase Plan. (Alterity Therapeutics) — high confidence, target: Q1 2024
- The capital raised will support ongoing research and development for neurodegenerative disease treatments. (Alterity Therapeutics) — medium confidence, target: Ongoing
FAQ
What is the primary purpose of Alterity Therapeutics' 6-K filing dated January 11, 2024?
The primary purpose of Alterity Therapeutics' 6-K filing is to announce the launch of a Security Purchase Plan (SPP) and to disclose that the company has received written commitments from institutional shareholders to purchase any shares not taken up by existing shareholders in the SPP.
Who signed the 6-K report on behalf of Alterity Therapeutics Limited?
The 6-K report was signed by Geoffrey P. Kempler, the Chairman of Alterity Therapeutics Limited, on January 11, 2024.
What is the significance of the 'continued support from institutional shareholders' mentioned in Exhibit 99.1?
The continued support from institutional shareholders is significant because it guarantees that Alterity Therapeutics will successfully raise the intended capital from the Security Purchase Plan, as these shareholders have committed to buying any shares not purchased by other investors.
Which stock exchanges does Alterity Therapeutics trade on, according to the filing?
According to the filing, Alterity Therapeutics trades on the ASX (ASX: ATH) and NASDAQ (NASDAQ: ATHE).
Into which registration statements is this Form 6-K being incorporated by reference?
This Form 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-01-11 17:16:25
Filing Documents
- ea191502-6k_alterity.htm (6-K) — 13KB
- ea191502ex99-1_alterity.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-003035.txt ( ) — 43KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 SPP with Continued Support from Institutional Shareholders 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: January 11, 2024 2